Results 281 to 290 of about 1,011,391 (359)

Study of various physiological changes in the blood of hepatitis B and C in Iraqi patients

Sally Hassan, Mark Farman, Rana T. Mohsen   +2 more
openalex   +2 more sources

Chronic hepatitis B in 2025: diagnosis, treatment and future directions. [PDF]

Clin Med (Lond)
Watson AG, Mulay AS, Gill US.
europepmc   +1 more source

Additional file 1 of Panduratin A from Boesenbergia rotunda suppresses hepatitis B virus by targeting HNF1α and synergizing with antiviral agents

Piyanoot Thongsri, Yongyut Pewkliang, Suparerk Borwornpinyo, Adisak Wongkajornsilp, Pakatip Ruenraroengsak, U Anurathapan, Abhasnee Sobhonslidsuk, Suradej Hongeng, Khanit Sa-ngiamsuntorn   +8 more
openalex   +1 more source

Eliminating perinatal transmission of hepatitis B virus: it is time for action

Journal of the International AIDS Society
Rania A. Tohme, Su Wang, Benjamin Cowie, Sandra Dudareva, Carolyn Wester   +4 more
doaj   +1 more source

Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs. [PDF]

Arch Virol
Sato Y, Doi K, Inoue J, Ninomiya M, Tsuruoka M, Sato K, Onuki M, Sawahashi S, Ouchi K, Watanabe K, Niitsuma H, Masamune A.   +11 more
europepmc   +1 more source

Liver-joint axis: Hepatitis B virus as a contributor to rheumatoid arthritis pathogenesis. [PDF]

Virulence
Wu H, Zhao N, Zhang X, Zhang Y, Wang H.
europepmc   +1 more source

Hepatitis B functional cure: Current and future perspective. [PDF]

World J Hepatol
Marrapu S, Soni JR, Kamal K, Kumar R.
europepmc   +1 more source

Hepatitis B surface antigen is upregulated by HIV Tat in an HIV-hepatitis B virus co-infection model system. [PDF]

Microbiol Spectr
Zhao W, Singh K, Sozzi V, Cevaal P, Rossello FJ, Martelotto L, Zerbato JM, Rhodes A, Powell DR, Schröder J, Anderson J, Tumpach C, Fong D, Revill P, Crane M, Grimmond S, Roche M, Audsley J, Lewin SR.   +18 more
europepmc   +1 more source

Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study. [PDF]

Front Med (Lausanne)
Feng Y, Zhou L, Shi S, Wang Z, Wang X, Du F.   +5 more
europepmc   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9-Based Strategies for Hepatitis B and C Treatment, and Challenges. [PDF]

J Cell Mol Med
Li MF, Zubair A, Wdidi S, He S.
europepmc   +1 more source